U.S. Food and Drug Administration (FDA) Investigation into ByHeart Formula
Table of Contents
The FDA investigated potential contamination issues related to infant formula produced by ByHeart, Inc. in 2023.
In February 2023, the FDA initiated an investigation after reports of Cronobacter sakazakii, a germ that can cause severe illness in infants, were linked to ByHeart formula. The FDA’s testing identified the presence of this germ in both a sample of finished formula and a sample of whole milk powder supplied to ByHeart.
The FDA stated the findings were not conclusive and continued to investigate the source of the contamination.ByHeart voluntarily recalled 120,000 cans of its infant formula in february 2023 as a precautionary measure.
Cronobacter Sakazakii and Infant Formula
Cronobacter sakazakii is a bacterium that can contaminate powdered infant formula and cause serious infections, including sepsis and meningitis, particularly in newborns and infants.
Symptoms of Cronobacter infection include fever, poor feeding, excessive crying, lethargy, and rash. The FDA emphasizes the importance of proper formula preparation and hygiene to minimize the risk of infection. According to the Centers for Disease Control and Prevention (CDC), Cronobacter infections are rare but have a high mortality rate.
as of February 23, 2023, the FDA reported four infant illnesses and two deaths potentially linked to ByHeart formula. FDA Press Proclamation
ByHeart’s Response and “Watershed Moment”
ByHeart characterized the FDA investigation as a “watershed moment” for the company, indicating a significant challenge and prospect for enhancement in its quality control processes.
The company voluntarily recalled its formula and cooperated with the FDA investigation. ByHeart stated it implemented enhanced testing protocols and worked to identify the source of the contamination. On March 1, 2023, ByHeart announced it had resumed limited formula production after implementing corrective actions. ByHeart Updates
As of January 24, 2024, there have been no further reported illnesses linked to ByHeart formula since the recall and implementation of corrective actions. FDA Investigation Update
FDA Recalls and safety Alerts
The FDA maintains a database of recalls and safety alerts related to food products, including infant formula. This resource provides consumers with details about potential hazards and steps to take to protect their health.
The FDA’s investigation into ByHeart formula highlights the importance of rigorous quality control measures in the infant formula industry. The agency continues to monitor the safety of infant formula products and take action to protect consumers. The FDA’s Infant Formula Safety page provides detailed information on regulations and safety measures.
